Restraining the Proliferation of Acute Lymphoblastic Leukemia Cells by Genistein through Up-regulation of B-cell Translocation Gene-3 at Transcription Level
AbstractBackground: Acute lymphoblastic leukemia (ALL) is a highly prevalent pediatric cancer accounting for approximately 78% of leukemia cases in patients younger than 15 years old. Different studies have demonstrated that B-cell translocation gene 3 (BTG3) plays a suppressive role in the progress of different cancers. Genistein is considered a natural and biocompatible compound and a new anti-cancer agent. In this study, we evaluate the effect of genistein on BTG3 expression and proliferation of ALL cancer cells. Materials and Methods: ALL cell lines (MOLT4, MOLT17, and JURKAT) were cultured in standard conditions. Cytotoxicity of genistein was detected using MTT assay. The cells were treated with different concentrations of genistein (10, 25, 40, and 55μM) for 24, 48, and 72 hours, and then cell viability and growth rate were measured. The quantitative real-time polymerase chain reaction was applied to investigate the effect of genistein on BTG3 expression. Results: The percentage of vital cells treated with genistein significantly decreased compared to the non-treated cells, showed an inverse relationship with an increasing genistein concentration. The present study suggests a dose of 40μM for genistein as a potent anticancer effect. Genistein could elevate BTG3 for 1.7 folds in MOLT4 and JURKAT and 2.7 folds in MOLT17 cell lines at transcription level conveged with 60 to 90% reduction in the proliferation rate of cancer cells. Conclusion: Up-regulation of BTG3 as a tumor suppressor gene can be induced by genistein. It seems that BTG3 reactivation can be introduced as another mechanism of anti-proliferative effect of genistein and could be considered as a retardant agent candidate against hematopoietic malignancy.[GMJ.2019;8:e1229]
Stiller C, Parkin D. Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull. 1996; 52(4): 682-703.
Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. The Lancet. 2013; 381(9881): 1943-1955.
Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004; 350(15):1535-48
Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008; 22(12):2142-50.
Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015; 125(26):3977-87.
Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest. 2012; 122(10): 3398-3406.
Jones PA, Laird PW. Cancer-epigenetics comes of age. Nat Genet. 1999; 21(2):163-7.
Cortes U, Moyret-Lalle C, Falette N, Duriez C, Ghissassi FE, Barnas C, et al. BTG gene expression in the p53‐dependent and‐independent cellular response to DNA damage. Mol Carcinog. 2000; 27(2):57-64.
Cheng YC, Lin TY, Shieh SY. Candidate tumor suppressor BTG3 maintains genomic stability by promoting Lys63-linked ubiquitination and activation of the checkpoint kinase CHK1. Proc Natl Acad Sci U S A. 2013; 110(15):5993-98.
Ou Y-H, Chung P-H, Sun T-P, Shieh S-Y. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. EMBO J. 2007; 26(17):3968-80.
Majid S, Altaf AD, Ardalan EA, Hiroshi H, Kazumori K, Varahram S, et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis. 2009; 30(4):662-70.
Yoneda M, Suzuki T, Nakamura T, Ajima R, Yoshida Y, Kakuta S, et al. Deficiency of antiproliferative family protein Ana correlates with development of lung adenocarcinoma. Cancer Sci. 2009; 100(2):225-232.
Yamamoto N, Uzawa K, Miya T, Watanabe T, Yokoe H, Shibahara T, et al. Analysis of the ANA gene as a candidate for the chromosome 21q oral cancer susceptibility locus. Br J Cancer. 2001; 84(6):754-62.
Lin T, Cheng YC, Yang HC, Lin WC, Wang CC, Lai PL, et al. Loss of the candidate tumor suppressor BTG3 triggers acute cellular senescence via the ERK-JMJD3-p16INK4a signaling axis. Oncogene. 2012; 31(27):3287-97.
Chen X, Chen G, Cao X, Zhou Y, Yang T, Wei S. et al., Downregulation of BTG3 in non-small cell lung cancer. Biochem Biophys Res Commun. 2013; 437(1):173-8.
Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, Kawamoto K, et al. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B‐Cell translocation gene 3 in prostate cancer. Cancer. 2010; 116(1):66-76.
Deng B, Zhao Y, Gou W, Chen S, Mao X, Takano Y, Zheng H. Decreased expression of BTG3 was linked to carcinogenesis, aggressiveness, and prognosis of ovarian carcinoma. Tumour Biol. 2013; 34(5):2617-24.
Lv Z, Zou H, Peng K, Wang J, Ding Y, Li Y, et al., The suppressive role and aberrent promoter methylation of BTG3 in the progression of hepatocellular carcinoma. PloS one. 2013; 8(10):77473.
Yu J, Zhang Y, Qi Z, Kurtycz D, Vacano G. Methylation-mediated downregulation of the B-cell translocation gene 3 (BTG3) in breast cancer cells. Gene Expr. 2007; 14(3):173-182.
Putnik M, Zhao C, Gustafsson JÅ, Dahlman-Wright K. Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 2012; 426(1):26-32.
Chen WF, Huang MH, Tzang CH, Yang M, Wong MS. Inhibitory actions of genistein in human breast cancer (MCF-7) cells. Biochim Biophys Acta Mol Basis Dis. 2003; 1638(2):187-96.
Peterson G, Barnes S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ. 1996; 7(10):1345-51.
Pagliacci M, Smacchia M, Migliorati G, Grignani F, Riccardi C, Nicoletti I. Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer. 1994; 30(11):1675-82.
Nikbakht M, Jha A.K, Malekzadeh3 K, Askari M, Mohammadi S, Marwaha R.K, Kaul D, Kaur J.Aberrant promoter hypermethylation of selected apoptotic genes in childhood acute lymphoblastic leukemia among north indian population. Exp Oncol. 2017; 39(1):57-64
Xiaoxia Liu X, Lianhua Y, Jingxin D, Hongyan J, Youji F. Genistein inhibits placental choriocarcinoma cell line JAR invasion through ERβ/MTA3/Snail/E-cadherin pathway. Oncol Lett. 2011; 2(5): 891-897.
Yong W, He W, Wei Z, Chen S, Chen S, Peng X, et al. Genistein sensitizes bladder cancer cells to hcpt treatment in vitro and in vivo via atm/nf-kb/ikk pathway-induced apoptosis. PLOS ONE. 2013; 8(1): e50175.
Yu D, Shin HS, Lee YS, Lee D, Kim S, Lee YC. Genistein attenuates cancer stem cell characteristics in gastric cancer through the downregulation of Gli1. Oncol Rep. 2014, 31(2):673-8.
Zhang S, Wang Y, Chen Z, Kim S, Iqbal S, Chi A. Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells. Prostate. 2013,73(15):1681-9.
Raghu Nadhanan R, Skinner J, Chung R, Su YW, Howe PR, Xian CJ. Supplementation with fish oil and genistein, individually or in combination, protects bone against the adverse effects of methotrexate chemotherapy in rats. PloS on. 2013, 8(8):e71592.
Huang W, Wan C, Luo Q, Huang Z. Genistein-inhibited cancer stem cell-like properties and reduced chemoresistance of gastric cancer. Int J Mol Sci. 2014,15(3):3432-43.
Yan GR, Zou FY, Dang BL, Zhang Y, Yu G, Liu X. Genistein-induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study. Proteomics. 2012, 12(14):2391-9.
Liu YL, Zhang GQ, Yang Y, Zhang CY, Fu RX, Yang YM, et al. Genistein induces G2/M arrest in gastric cancer cells by increasing the tumor suppressor PTEN expression. Nutr Cancer. 2013, 65(7):1034-41.
Ko KP, Park SK, Park B, Yang JJ, Cho LY, Kang C. Isoflavones from phytoestrogens and gastric cancer risk: a nested case-control study within the Korean Multicenter Cancer Cohort. Cancer Epidemiol Biomarkers Prev. 2010, 19(5):1292-300.
Carlo-Stella C1, Regazzi E, Garau D, Mangoni L, Rizzo MT, Bonati A, et al. Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. Br J Haematol. 1996, 93(3):551-7.
Li Y, Upadhyay S, Bhuiyan M, Sarkar FH. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene. 1999, 18(20): 3166 - 72.
Zhang LL, Li L, Wu DP, Fan JH, Li X, Wu KJ, et al. A novel anti-cancer effect of genistein: reversal of epithelial mesenchymal transition in prostate cancer cells. Acta Pharmacol Sin. 2008; 29(9): 1060-8.
Howard L, Parnes MD, William D, Pharm D. Chemoprevention in Prostate Cancer. Pharmacotherapy. 2006; 57: 1533.
Severson RK, Nomura AM, Grove JS, Stemmermann GN. A Prospective Study of Demographics, Diet, and Prostate Cancer among Men of Japanese Ancestry in Hawaii. Cancer Res. 1989; 49(7): 1857-60.
Maria R, Carmela S, Idolo T, Gian Luigi R. Phytochemicals in Cancer Prevention and Therapy: Truth or Dare?. Toxins. 2010; 2(4): 517-51.
Carmela S, Gian Luigi R, Ilkay Erdogan O, Solomon H, Maria D, Antoni S, et al. Genistein and Cancer: Current Status, Challenges, and Future Directions. Adv Nutr. 2015; 6(4): 408-19.
Russo M, Gian Luigi A, Daglia M, DeviKasi P, Ravi S, Nabavi SF, et al. Understanding genistein in cancer: The ''good" and the ''bad" effects: A review. Food Chem. 2016; 196: 589-600.
Henrique B, Eduardo P, Eduardo L, Nathalia C, Rodrigo A, Carina C, et al. Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. Prostate Cancer. 2013; 2013: 23.
Weiqi D, Lei H, Chunlei L, Shumei W, Ping C, Yan Z, et al. Genistein Inhibits Hepatocellular Carcinoma Cell Migration by Reversing the Epithelial-Mesenchymal Transition: Partial Mediation by the Transcription Factor NFAT1. Mol Carcinog. 2013; 54(4): 301-311.
Setchell K, Borriello SP, Hulme P, Kirk DN, Axelson M., Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr. 1984; 40(3):569-78.
Barnes S, Grubbs C, Setchell KD, Carlson J. Soybeans inhibit mammary tumors in models of breast cancer. Prog Clin Biol Res. 1990. 347: 239.
Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest. 1990; 50(sup201):3-23.
Fritz WA, Coward L, Wang J, Lamartiniere CA. Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenesis. 1998; 19(12):2151-8.
Peterson G, Barnes S., Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate. 1993; 22(4):335-5.
Constantinou A, Kiguchi K, Huberman E. Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res. 1990; 50(9):2618-24.
Lamartiniere CA. Protection against breast cancer with genistein: a component of soy. Am J Clin Nutr. 2000; 71(6):1705-7.
Xia J, Duan Q, Ahmad A, Bao B, Banerjee S, Shi Y, et al. Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Curr Drug Targets. 2012; 13(14):1750-6.
UniProtKB - Q14201 (BTG3_HUMAN). 2016; Available from: http://www.uniprot.org/uniprot/Q14201.
Qiagen Gene Globe. Cell Cycle Control by BTG Proteins. 2018; Available from: https://www.qiagen.com/us/shop/genes-and-pathways/pathway-details/?pwid=96
Gou Wf, Ang XF, Shen DF, Zhao S, Liu YP, Sun HZ,et al.,The roles of BTG3 expression in gastric cancer: a potential marker for carcinogenesis and a target molecule for gene therapy. Oncotarget. 2015; 6(23):19841.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).